Breaking Finance News

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded Pernix Therapeutics Holdings Inc(NASDAQ:PTX) to Hold in a report released on 8/18/2016.

Boasting a price of $0.79, Pernix Therapeutics Holdings Inc (NASDAQ:PTX) traded 4.69% higher on the day. With the last close up 25.75% from the two hundred day average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same time. PTX has logged a 50-day average of $0.67 and two hundred day moving average of $0.78. Trading volume was was down over the average, with 4,766,409 shares of PTX changing hands under the typical 5,856,810 shares.

Performance Graph:

Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

Pernix Therapeutics Holdings Inc has a 52 week low of $0.39 and a one-year high of $4.45 and has a market capitalization of $0.0.

In addition to Zacks Investment Research reporting it’s price target, a total of 4 analysts have reported on Pernix Therapeutics Holdings Inc. The 12-month target price is $7.00 with three analysts rating the company a strong buy, one analyst rating the stock a buy, 0 firms rating the stock a hold, 0 rating the company to underperform, and finally 0 brokeragesrating the stock as sell.

General Company Details For Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, and Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *